Investor's Business Daily on MSN7d
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.
STAT8d
Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...
BioSpace5d
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...
ENDPOINTS NEWS8d
De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval
Axsome Therapeutics on Monday reported data for two Phase 3 studies in Alzheimer’s-related agitation, saying one trial ...
MedCity News8d
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data
Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its latest slate of ...
What we know about man who fatally beat Delaware assisted living facility resident
A resident who lived across the hall from Hsia in the facility's memory care unit left her bleeding and unconscious on the ...
AOL7d
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...
Reuters8d
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data
Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...
Axsome data support Alzheimer’s agitation approval, says Wells Fargo
Wells Fargo says that while the ADVANCE-2 miss makes the regulatory path less certain, the totality of the data supports approval for Axsome ...
Morningstar8d
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared ...